

Ignacio Pérez Catalán ^{a,*}, Celia Roig Martí ^a,
Jorge Andrés Soler ^a, Sergio Fabra Juana ^a,
Bárbara Gomila Sard ^b, Jorge Usó Blasco ^a y José Antonio Caminero ^c

^a Medicina Interna, Hospital General Universitario de Castellón,
Castellón de la Plana, España

^b Microbiología Clínica, Hospital General Universitario de Castellón,
Castellón de la Plana, España

^c Unidad de Tuberculosis y Otras Micobacteriosis, Servicio
de Neumología, Hospital General de Gran Canaria Dr. Negrín,
Las Palmas, España

* Autor para correspondencia.

Correo electrónico: nachocs13@gmail.com (I. Pérez Catalán).

<https://doi.org/10.1016/j.arbres.2020.08.021>

0300-2896/ © 2020 SEPAR. Publicado por Elsevier España, S.L.U. Todos los derechos reservados.

Combined Diaphragm and Limb Muscle Atrophy Is Associated With Increased Mortality in Mechanically Ventilated Patients: A Pilot Study



La combinación de atrofia del diafragma y atrofia de los músculos de las extremidades se asocia a un aumento de la mortalidad en los pacientes con ventilación mecánica: un estudio piloto

Dear Editor,

Patients admitted to the intensive care unit (ICU) are at high risk of developing peripheral and respiratory muscle compromise.^{1–3} ICU-acquired limb muscle weakness (ICUAW) and ventilator-induced diaphragm dysfunction (VIDD) are the hallmarks of myopathy affecting critically ill patients. The presence of either ICUAW or VIDD is associated with poorer outcomes, including prolonged mechanical ventilation, ICU stay and mortality.^{1,2,4–8} Muscle wasting plays a central role in the development of skeletal muscle weakness. Limb and respiratory muscle atrophy occurs rapidly in critically ill patients.^{9,10} Few studies have analyzed the development of ICUAW and VIDD in the same subjects, and reports describing the evolutionary pattern of muscle wasting affecting both peripheral and respiratory muscles in critically ill patients are scarce.^{2,11–15} Dres et al. demonstrated that limb muscle and severe diaphragm weakness have a cumulative negative impact on patients' outcome.¹² Whether peripheral muscle and diaphragm atrophy also have a cumulative impact is unknown.

The aim of this pilot study was to describe the evolutionary pattern of limb muscle and diaphragm thickness in critically ill patients requiring mechanical ventilation, and to determine whether the combination of limb and diaphragmatic atrophy has a cumulative impact on patients' outcome.

Thirty-two adult patients admitted to ICU and requiring invasive mechanical ventilation were included. Diaphragm, mid-upper arm, mid-forearm and mid-thigh muscle thickness were measured by ultrasound on admission and repeated on days three and seven (Supplementary Fig. 1). Diaphragmatic atrophy was defined as a decrease in diaphragm thickness $\geq 5\%$ from baseline. Limb muscle atrophy was considered when any of the peripheral muscles had a decrease in thickness $\geq 5\%$ from baseline. Subjects associating diaphragmatic and limb muscle atrophy were considered to present combined muscle atrophy.

Categorical variables were reported as absolute numbers (percentage) and compared using Chi-square test or Fisher exact test. Continuous variables were expressed as mean \pm standard deviation if normally distributed, or median (25th, 75th percentile) if not. Student *t* test was used to compare initial muscle thickness between groups. Mann-Whitney *U* test was performed to compare muscle thickness change from baseline between atrophy and no-atrophy groups at each time point. The Spearman correlation was used to analyze bivariate correlations. A *P* value < 0.05 was considered sta-

tistically significant. A more detailed description of the methods is provided in the Supplementary material.

Patients' characteristics are summarized in Supplementary Table 1. Median time on mechanical ventilation was 11 (5, 13) days and ICU mortality was 25%. During the first week, patients were mostly ventilated in assisted/controlled modes. All 24 patients that survived after ICU admission were weaned from mechanical ventilation (20 extubated, 4 tracheostomized after the first week) and discharged alive from the hospital. Mean baseline diaphragm thickness on admission was 1.7 ± 0.5 mm. This measurement was slightly higher in men versus women (1.9 ± 0.4 mm vs. 1.5 ± 0.6 mm, *P* = 0.066), but not statistically significant. Diaphragm thickness evolution was explored in 29 subjects. Twenty (69%) subjects developed diaphragm atrophy during the first week after ICU admission. In this group of subjects, diaphragm thickness change from baseline was -10.3% ($-17.8\%, 0.0\%$) on day 3 and -15.8% ($-30.7\%, -5.5\%$) on day 7 (*P* = 0.010 and *P* = 0.003 compared with subjects without diaphragm atrophy, respectively; Fig. 1A).

Mean arm, forearm and thigh baseline muscle thickness were 2.49 ± 0.62 cm, 3.24 ± 0.53 cm and 3.01 ± 0.54 cm, respectively. Overall, men presented higher peripheral muscle thickness than women on admission (arm: 2.60 ± 0.68 cm vs. 2.20 ± 0.33 cm, *P* = 0.033; forearm: 3.34 ± 0.55 cm vs. 2.97 ± 0.38 cm, *P* = 0.079; thigh: 3.19 ± 0.45 cm vs. 2.56 ± 0.51 cm, *P* = 0.002). Evolution of arm muscle thickness was explored in 31 subjects, 12 (38.7%) of whom developed atrophy. Evolution of forearm and thigh muscle thickness could be measured in 29 subjects. Forearm atrophy was observed in 11 (37.9%) subjects, while 10 (34.5%) subjects acquired quadriceps atrophy. The change in limb muscles thickness was significantly different among patients with or without atrophy (Fig. 1B–D). When considering the evolution of all three peripheral sites, 19 (61.3%) patients developed limb muscle atrophy affecting at least one of the explored muscles.

Thirteen (44.8%) subjects presented an association of diaphragmatic and limb muscle atrophy (Fig. 1E). The combination of respiratory and limb muscle atrophy was the most common profile (44.8%), as compared to patients presenting only diaphragmatic atrophy (20.7%), only peripheral muscle atrophy (13.8%) or no atrophy at all (20.7%). No significant correlation was found between the maximum decrease in diaphragm and limb muscle thickness ($r_s = 0.336$, *P* = 0.075).

Demographic, clinical or therapeutic characteristics and baseline muscle thickness were similar among patients who developed atrophy and those who did not (Supplementary Tables 2–4 and Supplementary Fig. 2).

Baseline thickness of all the explored muscles was also similar between survivors and non-survivors (Supplementary Fig. 3). Duration of mechanical ventilation, ICU and hospital length of stay was not significantly different between subjects with or without diaphragmatic, limb or combined muscle atrophy (Supplementary Tables 2–4). Although there was a trend towards increased mortality in subjects who developed diaphragm atrophy and those who




Fig. 1. (A) Change in diaphragm thickness over time in subjects with and without diaphragmatic atrophy. (B-D) Change in mid-upper arm (B), mid-forearm (C) and mid-thigh (D) muscle thickness over time in subjects with and without limb muscle atrophy. (E) Relationship between maximum decrease in diaphragm and limb muscle thickness. Dashed lines represent the cutoff change in muscle thickness to define atrophy (-5% from baseline). Symbols and bars in A-D represent median and 25th–75th percentiles. ** = $P \leq 0.01$, *** = $P < 0.001$, between groups at selected time points. r_s = Spearman's correlation coefficient.

developed limb muscle atrophy compared to those who did not, these differences did not reach statistical significance. On the contrary, subjects associating diaphragm and limb muscle atrophy had a significantly higher ICU mortality than the rest (38.5% vs. 6.3%, $P = 0.047$, Supplementary Table 4).

Being a pilot study, the principal limitations are related to the reduced sample size. Therefore, results must be interpreted with caution until confirmed in further studies involving a greater number of patients. Also, muscle function was not assessed and data regarding nutritional support was not obtained.

In conclusion, distinct atrophy profiles can be identified in critically ill patients. While muscle mass surrogates measured upon ICU admission may provide information related to the patient previous condition, their evolutionary pattern probably reflects a combination of the patient's premorbid status and concurrent critical disease and treatment. Therefore, serial muscular evaluation could be of greater importance than a single measurement at any time point. To the best of our knowledge, this is the first report of a

cumulative impact of diaphragm and limb muscle wasting on ICU mortality.

Authors' contributions

MA designed the study; AC enrolled the subjects and performed the ultrasounds; AC, SP, MB and MA contributed substantially to the data analysis and interpretation; AC and MA wrote the manuscript.

Funding

None.

Conflicts of interest

None.

Appendix A. Supplementary data

Supplementary data associated with this article can be found, in the online version, at doi:10.1016/j.arbres.2020.12.031.

Bibliografía

1. De Jonghe B, Sharshar T, Lefacheur JP, Authier FJ, Durand-Zaleski I, Boussarsar M, et al. Paresis acquired in the intensive care unit: a prospective multicenter study. *JAMA*. 2002;288:2859–67.
2. Dres M, Dube BP, Mayaux J, Delemazure J, Reuter D, Brochard L, et al. Coexistence and impact of limb muscle and diaphragm weakness at time of liberation from mechanical ventilation in medical intensive care unit patients. *Am J Respir Crit Care Med*. 2017;195:57–66.
3. Barreiro E. Models of disuse muscle atrophy: therapeutic implications in critically ill patients. *Ann Transl Med*. 2018;6:29.
4. Ali NA, O'Brien JM Jr, Hoffmann SP, Phillips G, Garland A, Finley JC, et al. Acquired weakness handgrip strength, and mortality in critically ill patients. *Am J Respir Crit Care Med*. 2008;178:261–8.
5. Sharshar T, Bastuji-Garin S, Stevens RD, Durand MC, Malissin I, Rodriguez P, et al. Presence and severity of intensive care unit-acquired paresis at time of awakening are associated with increased intensive care unit and hospital mortality. *Crit Care Med*. 2009;37:3047–53.
6. Supinski GS, Callahan LA. Diaphragm weakness in mechanically ventilated critically ill patients. *Crit Care*. 2013;17:R120.
7. Medina C, Prieur G, Freney E, Robledo Quesada A, Poncet A, Bonnevie T, et al. Respiratory weakness after mechanical ventilation is associated with one-year mortality – a prospective study. *Crit Care*. 2016;20:231.
8. Goligher EC, Dres M, Fan E, Rubenfeld GD, Scales DC, Herridge MS, et al. Mechanical ventilation-induced diaphragm atrophy strongly impacts clinical outcomes. *Am J Respir Crit Care Med*. 2018;197:204–13.
9. Puthucheary ZA, Rawal J, McPhail M, Connolly B, Ratnayake G, Chan P, et al. Acute skeletal muscle wasting in critical illness. *JAMA*. 2013;310:1591–600.
10. Levine S, Nguyen T, Taylor N, Friscia ME, Budak MT, Rothenberg P, et al. Rapid disuse atrophy of diaphragm fibers in mechanically ventilated humans. *N Engl J Med*. 2008;358:1327–35.
11. De Jonghe B, Bastuji-Garin S, Durand MC, Malissin I, Rodrigues P, Cerf C, et al. Respiratory weakness is associated with limb weakness and delayed weaning in critical illness. *Crit Care Med*. 2007;35:2007–15.
12. Dres M, Jung B, Molinari N, Manna F, Dube BP, Chanques G, et al. Respective contribution of intensive care unit-acquired limb muscle and severe diaphragm weakness on weaning outcome and mortality: a post hoc analysis of two cohorts. *Crit Care*. 2019;23:370.
13. Jung B, Nougaré S, Conseil M, Coisel Y, Futier E, Chanques G, et al. Sepsis is associated with a preferential diaphragmatic atrophy: a critically ill patient study using tridimensional computed tomography. *Anesthesiology*. 2014;120:1182–91.
14. Baldwin CE, Bersten AD. Alterations in respiratory and limb muscle strength and size in patients with sepsis who are mechanically ventilated. *Phys Ther*. 2014;94:68–82.
15. Vivier E, Roussey A, Doroszewski F, Rosselli S, Pommier C, Carteaux G, et al. Atrophy of diaphragm and pectoral muscles in critically ill patients. *Anesthesiology*. 2019;131:569–79.

Agustín Carámbula ^{a,b}, Sebastián Pereyra ^c, Marcelo Barbato ^a, Martín Angulo ^{a,d,e,*}

^a Intensive Care Unit, Hospital Maciel, Montevideo, Uruguay

^b National Institute of Cell, Tissue, and Organ Donation and Transplantation, Montevideo, Uruguay

^c Department of Diagnostic Ultrasound, Hospital Maciel, Montevideo, Uruguay

^d Respiratory Function Laboratory and Critical Care Department, School of Medicine, Universidad de la República, Montevideo, Uruguay

^e Pathophysiology Department, School of Medicine, Universidad de la República, Montevideo, Uruguay

* Corresponding author.

E-mail address: martin.angulo@hc.edu.uy (M. Angulo).

<https://doi.org/10.1016/j.arbres.2020.12.031>

0300-2896/ © 2021 SEPAR. Published by Elsevier España, S.L.U. All rights reserved.

16 Years in the Trachea



16 años en la tráquea

Dear Editor,

Malignant airway obstruction (MAO) often complicates the course of oncological diseases, specially lung cancer. Bronchoscopic evaluation and intervention is of utmost importance in MAO management.¹ In selected cases, airway stenting is needed to maintain airway patency either in a purely palliative setting or as a bridge until adequate response to systemic treatment is achieved. Silicone stents can only be placed by rigid bronchoscopy under general anaesthesia, but are easy to remove.² However, stent-related complications are not negligible and seem to be time-dependent.³ Although yearly switch is recommended by the manufacturer, the real durability of Dumon® stent is unknown. We report a case of a 58 year old female with MAO due to an atypical carcinoid of the lung managed with silicone stent for 16 years.

The patient was diagnosed with an atypical carcinoid of the lung at age of 21 and underwent left pneumonectomy. After 18 years, disease recurrence was detected. A thoracic CT scan showed a mass involving the lower third of the trachea and the right main bronchus, causing significant endoluminal airway obstruction (90%). Rigid bronchoscopy was performed and after mechanical debulking, airway patency was still not satisfactory, therefore, a Dumon® stent was placed in the trachea and right main bronchus with clinical improvement. Two years later, she presented in the emergency department with severe stridor. An emergent rigid bronchoscopy showed proximal obstruction of the right main bronchus with tumoral tissue and, after laser therapy and mechanical debulking, a

distal stent migration to the right main bronchus was observed. The procedure was complicated by severe haemorrhage leading to respiratory failure requiring mechanical ventilation and subsequent intensive care unit admission. After fourteen days of invasive ventilation and stabilization, the stent was replaced and positioned in distal trachea and proximal right main bronchus. After nine days, she was extubated and discharged to Pulmonology ward. Despite clinical improvement, the patient was diagnosed with critical illness myopathy and polyneuropathy requiring intensive physical rehabilitation. Additionally, distant multifocal metastatic disease including skin and bone was found. Since the tumor revealed positivity for somatostatin receptors in octreotide scan, systemic treatment with somatostatin analogues was initiated. Regular bronchoscopic evaluations were performed showing appropriate stent positioning. Progressive shrinkage of the mass was observed and adequate airway patency was achieved being possible to safely remove the stent after 16 years (Fig. 1). Despite the clinical stability, during this time, the patient experienced severe halitosis with negative impact in her social life and, in the last 2 years of stenting, frequent respiratory infections were observed. Currently, the patient is asymptomatic.

Airway stenting is indicated in a variety of malignant and benign diseases and has as main function supporting and maintain the airway lumen patency. In malignancy, the indications of its use include airway obstruction either due extrinsic compression or persistence of residual endobronchial lesions after mechanical debulking and/or thermal therapies, cartilage destruction by tumor and tracheoesophageal fistulas.⁴ Stenting also avoids the tumor re-growth and obstruction recurrence at some extent. Although any type of malignancy may cause airway obstruction, either as primary or metastatic, the most com-